In bladder cancer cells in vitro and in bladder tumor in vivo, we demonstrated that PPARĪ³ active DIM-Cs showed significant anti-tumorigenic activity and were more potent inhibitors of bladder cancer growth when compared with rosiglitazone, the currently used synthetic PPARĪ³ agonist [16].
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}